Fosun sees stellar H1 expansion
Print Edition
FOSUN Pharma Group turned in strong double-digit growth in revenue and profit as well as overseas income in the first half of the year, the Chinese pharmaceutical company said yesterday.
The company posted a 20.4 percent jump in revenue to 8.35 billion yuan (US$1.24 billion) while profit added 12.6 percent from a year ago to 1.69 billion yuan. Income from overseas surged 58.6 percent annually to 1.47 billion yuan amid its successful global strategy.
In the first six months, revenue from pharmaceutical manufacturing and research and development totaled 5.77 billion yuan, up 19.12 percent annually while that of its healthcare business gained 37 percent from a year ago to 1.01 billion yuan.
The group said it spent 626 million yuan on research and development in the first half, up 28 percent from the same period a year ago.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
